Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Institute of Forensic Medicine, Forensic Toxicology, Medical Center, University of Freiburg, Freiburg, Germany.
Arch Toxicol. 2024 Oct;98(10):3337-3350. doi: 10.1007/s00204-024-03830-2. Epub 2024 Aug 8.
Synthetic cannabinoid receptor agonists (SCRAs) are a class of synthetic drugs that mimic and greatly surpass the effect of recreational cannabis. Acute SCRA intoxications are in general difficult to assess due to the large number of compounds involved, differing widely in both chemical structure and pharmacological properties. The rapid pace of emergence of unknown SCRAs hampers on one hand the timely availability of methods for identification and quantification to confirm and estimate the extent of the SCRA intoxication. On the other hand, lack of knowledge about the harm potential of emerging SCRAs hampers adequate interpretation of serum concentrations in intoxication cases. In the present study, a novel comparative measure for SCRA intoxications was evaluated, focusing on the cannabinoid activity (versus serum concentrations), which can be measured in serum extracts with an untargeted bioassay assessing ex vivo CB activity. Application of this principle to a series of SCRA intoxication cases (n = 48) allowed for the determination of activity equivalents, practically entailing a conversion from different SCRA serum concentrations to a JWH-018 equivalent. This allowed for the interpretation of both mono- (n = 34) and poly-SCRA (n = 14) intoxications, based on the intrinsic potential of the present serum levels to exert cannabinoid activity (cf. pharmacological/toxicological properties). A non-distinctive toxidrome was confirmed, showing no relation to CB activity. The JWH-018 equivalent was partly related to the poison severity score (PSS) and causality of the clinical intoxication elicited by the SCRA. Altogether, this equivalent concept allows to comparatively and timely interpret (poly-)SCRA intoxications based on CB activity.
合成大麻素受体激动剂 (SCRAs) 是一类模拟并大大超过娱乐性大麻效果的合成药物。由于涉及的化合物数量众多,且在化学结构和药理学特性上差异很大,急性 SCRAs 中毒通常难以评估。未知 SCRAs 的快速出现一方面阻碍了及时获得用于鉴定和定量的方法来确认和估计 SCRAs 中毒的程度,另一方面,缺乏对新兴 SCRAs 的潜在危害的认识阻碍了对中毒情况下血清浓度的充分解释。在本研究中,评估了一种用于 SCRAs 中毒的新型比较测量方法,重点关注大麻素活性(与血清浓度相比),可以用评估体外 CB 活性的非靶向生物测定法测量血清提取物中的活性。将这一原理应用于一系列 SCRAs 中毒病例(n=48),可以确定活性当量,实际上可以将不同 SCRAs 血清浓度转换为 JWH-018 当量。这允许基于目前血清水平发挥大麻素活性的内在潜力(比较药理学/毒理学特性)来解释单(n=34)和多-SCRAs(n=14)中毒。确认了一种无明显中毒症状,表明与 CB 活性无关。JWH-018 当量部分与 SCRAs 引起的中毒严重程度评分(PSS)和因果关系有关。总的来说,这个等效概念允许基于 CB 活性对(多)SCRAs 中毒进行比较和及时解释。